Daré Bioscience Inc (DARE)
NASDAQ:DARE
Want to see DARE full AI Analyst Report?
DARE Stock Chart & Stats
$1.70
-$0.06(-1.78%)
At close: 4:00 PM EST
$1.70
-$0.06(-1.78%)
Day’s Range― - ―
52-Week Range$1.27 - $9.19
Previous CloseN/A
Volume4.87K
Average Volume (3M)170.74K
Market Cap
$28.16M
Enterprise Value$9.90M
Total Cash (Recent Filing)$18.52M
Total Debt (Recent Filing)$7.18M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding14,979,502
10 Day Avg. Volume281,723
30 Day Avg. Volume170,743
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-21.01
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue8.55
Enterprise Value/Gross Profit153.55
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$10.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$1.99M
Bulls Say, Bears Say
Bulls Say
Nondilutive Grant FundingMaterial grant awards provide significant nondilutive capital and contra‑R&D offsets that extend runway for trials and development. This funding lowers near‑term dilution risk, sustains R&D activity, and enables continued regulatory and clinical progress without immediate equity raises.
Near‑Term Commercial CatalystsImminent product launches create the company’s first direct revenue streams and the potential to diversify income away from grants. Successful commercialization would validate go‑to‑market capabilities, improve cash generation, and materially de‑risk follow‑on financing needs over the medium term.
Broad Pipeline & Dual Commercial PathExecuting both 503B and 505(b)(2) pathways across several women’s health assets reduces single‑point regulatory risk and staggers market entry. Multiple programs and routes to market increase the chance of creating recurring revenue streams and build durable competitive positioning.
Bears Say
Negative Cash FlowSustained negative operating and free cash flow shows the business is consuming cash to fund operations and trials. Continued cash burn limits strategic flexibility, heightens reliance on external financing, and increases the probability of dilutive capital raises that can impair long‑term shareholder economics.
Balance‑Sheet InstabilityVery thin and volatile equity with elevated leverage reduces the firm’s financial cushion and raises solvency concerns under stress. Historical swings in equity and episodes of negative equity signal heightened financing vulnerability and likely future dilution to sustain development and commercialization plans.
Limited Near‑Term LiquidityWorking capital is minimal and management notes sub‑12‑month runway without new revenue or financing. This makes timely execution of launches and state registrations critical; any commercial or regulatory delay could force accelerated, potentially costly financing and impair program timelines.
Daré Bioscience News
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $1.27 and its highest was $9.19 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is $28.16M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on May 14, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.105.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.3.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 14,979,502 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went down -24.126%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
DARE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and catalytic picture: multiple near-term commercial milestones (Flora Sync LF5 launch in June, DARE to PLAY dispensing targeted this summer, first product revenue for the company) and positive clinical progress (Ovaprene DSMB review, DARE-HPV IND and Phase II start) are strong positives. These are balanced against material execution and financing risks — limited cash/working capital, need to raise capital absent revenue, state-by-state fulfillment delays and tolerability-related discontinuations in the Ovaprene trial. On net, the multiple commercial and clinical catalysts combined with significant nondilutive grant funding and clear go-to-market plans slightly outweigh the operational and liquidity headwinds.View all DARE earnings summariesDARE Stock 12 Month Forecast
Average Price Target
$10.00
▲(488.24% Upside)
Technical Analysis
Vyome Holdings
―
Lunai Bioworks
―
Passage Bio
―
Neurosense Therapeutics Ltd.
―
Boundless Bio Inc.
―
Ownership Overview
7.10%
Insiders
3.88% Mutual Funds
0.08% Other Institutional Investors
85.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---